RECRUITING

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Official Title

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Quick Facts

Study Start:2024-12-10
Study Completion:2029-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06299436

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult patients aged between 18 and 90 years of age
  2. * Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40%)
  3. * Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure
  1. * Unable to interrupt VKA anticoagulation
  2. * Point of care International Normalized Ratio (INR) \> 1.5
  3. * Pregnant patients
  4. * Acute hospitalization or decompensation within 2 weeks prior to study date
  5. * Participation in a study involving an investigational drug within 4 weeks prior to study date
  6. * Inability to lie flat in the supine position
  7. * Symptomatic hemodynamic instability at rest or during the procedure

Contacts and Locations

Study Contact

Steven Hsu, MD
CONTACT
410-502-0955
steven.hsu@jhmi.edu

Principal Investigator

Steven Hsu, MD
PRINCIPAL_INVESTIGATOR
Johns Hopkins School of Medicine

Study Locations (Sites)

Johns Hopkins Hospital
Baltimore, Maryland, 21287
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Steven Hsu, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-10
Study Completion Date2029-03-31

Study Record Updates

Study Start Date2024-12-10
Study Completion Date2029-03-31

Terms related to this study

Keywords Provided by Researchers

  • right heart failure
  • heart failure
  • cardiomyopathy
  • pulmonary hypertension
  • heart failure with reduced ejection fraction

Additional Relevant MeSH Terms

  • Heart Failure With Reduced Ejection Fraction
  • Pulmonary Hypertension
  • Right Heart Failure Due to Left Heart Failure